Key scientists of Chiralabs include:
The Chiralabs scientific effort is overseen and guided by George E. Tranter PhD MA BSc FRSC CChem CSi, who has held senior R&D positions in both industry and academia (including at London University, Oxford University, the Wellcome Foundation and GlaxoWellcome). Until 2006 he led the Biospectroscopy Centre of Imperial College London and subsequently was Senior Research Fellow of the Department of Chemistry, University of Oxford. He is a recognised international authority in the field of molecular chirality and the spectroscopic/physicochemical features of drugs and biopharmaceuticals. He is named as inventor on drug patents, has published widely in the scientific literature, co-edited The Encyclopaedia of Spectroscopy & Spectrometry (Academic Press), has been a member of scientific journal editorial boards (inc. CHIRALITY) and appeared on radio and television programmes in the UK and abroad. He is also a member of various scientific advisory panels and is a key partner in collaborations that bring together the biopharmaceutical industry, academia and governmental institutions to investigate and validate biopharmaceutical structure and function. His particular interests are in the rational discovery of new therapeutics, with a passion for the role chirality plays in nature, from the molecular level through to macroscopic structures (e.g. helical shells) and beyond.
The Science Director is Delphine D. Le Pevelen Dr DEA MSP LSP DEUG, an expert in crystallography and the crystal growth of natural and synthetic compounds, particularly pharmaceuticals and organometallics (inc. metallo-drugs). She is co-inventor of the internationally award-winning rational crystallisation screening technology CrystalGEM and an authority on the properties of solvent/anti-solvent systems. Dr Le Pevelen has held research positions in leading university laboratories in the UK and France and is a regular contributor to scientific meetings and symposia. Her particular interests are in solving complex crystal structures and understanding crystal growth phenomena, including the rationalisation and control of polymorphism, enantiomorphism, morphology, solvates, salts and co-crystal formation.
Specialist expertise in physicochemical and electrochemical phenomena is provided by Ann M. Talbert PhD MSc BSc, the Principal Scientist of the Company, who has extensive experience of drug discovery and optimisation in the pharmaceutical industry. She is also the developer of novel analytical techniques for studying protein-ligand interactions using immobilised protein phases. Her other interests include the nucleation and crystallisation of drug molecules and the use of spectroscopy for characterising pharmaceuticals in solution and the solid state. Dr Talbert is also our qualified in-house expert on the effects of nutrition on human metabolism and disease states.